Summary Background Direct oral anticoagulants (DOACs) are effective and safe alternatives
to warfarin for stroke prophylaxis for atrial fibrillation (AF). Whether this extends to patients at …

Introduction oral anticoagulant (DOAC) agents are becoming the anticoagulation strategy of
choice for most clinical risks for which they are indicated. However, residual uncertainty …

Background Several studies have shown the cost-effectiveness of direct oral anticoagulants
(DOACs), compared with warfarin, to prevent atrial fibrillation (AF) related complications …

Abstract Background and Objectives Atrial fibrillation (AF) and the associated risk of stroke
are emerging epidemics throughout the world. Suboptimal use of oral anticoagulants for …

Background: Direct oral anticoagulants (DOACs) have the potential to improve stroke
prevention among atrial fibrillation (AF) patients. We sought to determine if oral …

Background Clinical trials have demonstrated that direct oral anticoagulants (DOAC) are
non‐inferior to vitamin K antagonist for stroke prevention in non‐valvular atrial fibrillation …

Aims To investigate trends in the prescription of oral anticoagulants (OACs) and antiplatelet
agents for atrial fibrillation (AF). Methods and results Prescription data for 450 518 patients …

BACKGROUND: Atrial fibrillation is associated with substantial mortality and morbidity from
stroke and thromboembolism. Despite an efficacious oral anticoagulation therapy (warfarin) …

Background Direct‐acting oral anticoagulants are now the preferred method of
anticoagulation in patients with atrial fibrillation. Limited data on efficacy and safety of these …

Direct oral anticoagulants (DOACs) are a favored treatment to prevent stroke in patients with
atrial fibrillation (AF). There are limited data concerning the efficacy and safety of DOACs in …